Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome - 06/08/11
, Oscar Bazzino, MD b, e, Jose Luis Navarro Estrada, MD b, Raul de Miguel, Lic b, Simon Salzberg, MD c, Juan J. Fuselli, MD d, Christoph Liebetrau a, Mariella Woelken, MD a, Helge Moellmann, MD a, Holger Nef, MD a, Christian Hamm, MD aRésumé |
Background |
In the present study, we aimed to analyze the diagnostic and prognostic potential of a newly developed high-sensitive troponin T assay and compared these results with those of a contemporary troponin T assay in 2 distinct patient cohorts, one including patients with evident ACS and the other one including patients with general chest pain.
Methods and Results |
For this study, we analyzed data from 2 independent patient cohorts, the Bad Nauheim ACS registry and the Prognosis in Acute Coronary Syndromes registry, with a total of 2,506 patients. On admission, clinical data have been recorded, and a single measurement of troponin T has been performed with a contemporary assay (TnT) and a new high-sensitive troponin T assay (hsTnT). Clinical follow-up has been obtained after 6 months. The diagnostic value of hsTnT was superior to TnT (area under the receiver operating characteristic curve 0.949 vs 0.929, P = .016). Specifically, in TnT-negative patients, hsTnT provided strong diagnostic information (area under the receiver operating characteristic curve of 0.81, P < .001). Furthermore, hsTnT provided independent prognostic power for mortality within 6 months in both cohorts, which was superior to that of the contemporary TnT assay.
Conclusion |
Troponin T measured with a newly developed hsTnT provides better diagnostic and prognostic information and, therefore, should be implemented as a standard test in clinical routine.
Le texte complet de cet article est disponible en PDF.Plan
Vol 162 - N° 1
P. 81-88 - juillet 2011 Retour au numéro
Article précédent
- Prevalence and correlates of smoking cessation pharmacotherapy in hospitalized smokers with acute myocardial infarction
- David A. Katz, Fengming Tang, Babalola Faseru, Phillip A. Horwitz, Philip Jones, John Spertus
- Cardiogenic shock and heart failure post–percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from “Assessment of Pexelizumab in Acute Myocardial Infarction”
- John K. French, Paul W. Armstrong, Eric Cohen, Neal S. Kleiman, Christopher M. O'Connor, Anne S. Hellkamp, Amanda Stebbins, David R. Holmes, Judith S. Hochman, Christopher B. Granger, Kenneth W. Mahaffey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?